Table 3.

Main characteristics of patients with atypical hemolytic uremic syndrome who relapsed or not after eculizumab discontinuation

Patient CharacteristicsRelapsers, n=12Nonrelapsers, n=26P Value
Women7 (58)17 (65)0.95
Age, yr
Adults25 (20–37)36 (21–79)0.02
Children6 (2–9)9 (5–17)0.45
Patients with ≥1 aHUS episode before eculizumab use6 of 12 (50)3 of 26 (11)0.03
HD at onset6 of 12 (50)12 of 26 (46)0.89
Duration of eculizumab treatment, mo14 (2–50)14.5 (3–45)0.95
SCr at eculizumab discontinuation, mg/dl
Adults1 (0.76–1.1)1 (0.65–2.8)0.55
Children0.4 (0.25–0.45)0.42 (0.4–0.44)0.90
Variants
CFH8 (67)3 (11)0.002
MCP4 (33)4 (15)0.20
 No variant016 (62)<0.001
Follow-up after eculizumab discontinuation, mo21.5 (15–38)21.1 (5–43)0.96
  • Values are shown as n (%) or as median (full range). aHUS, atypical hemolytic uremic syndrome; HD, hemodialysis; SCr, serum creatinine; CFH, complement factor H; MCP, membrane cofactor protein.